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Abstract Postmenopausal women more often suffered from
knee osteoarthritis and its pathogenesis still remains unclear.
Calcium and silicon are significant elements involved in bone
and joint metabolism, especially in older people.
Cardiovascular diseases are common worldwide and simva-
statin is the most prescribed drug in such population of pa-
tients. The purpose of this study was to evaluate the effect of
simvastatin administration on calcium and silicon concentra-
tion in the plasma of postmenopausal women with osteoarthri-
tis. Sixty postmenopausal mild hypercholesterolemic
women (mean age 61.4 years, range 54–68) were en-
rolled. Thirty patients received simvastatin (20 or
40 mg/day) for at least 1 year before being enrolled
(simvastatin B+^ group). Control group consists of re-
maining 30 women (simvastatin B−Bgroup). Silicon and
calcium concentrations were measured spectrophotomet-
rically. Plasma simvastatin level was determined 3 h
after the drug administration using HPLC-UV-Vis.
Calcium but not silicon level was significantly lower
in patients receiving simvastatin in comparison with
non-statin group (1.91 ± 0.32 vs. 2.33 ± 0.19 mmol/l,
p < 0.05). A weak but significant positive correlation
between plasma silicon and simvastatin levels (r = 0.3,
p < 0.05) was observed; this may be due to the fact that
simvastatin contains silicon dioxide as an inactive
ingredient. The mean simvastatin concentration was
9.02 ng/ml. All hypotheses were verified at the signifi-
cance level of p < 0.05. A statistically significant de-
crease in the plasma calcium concentration of postmen-
opausal women, treated with simvastatin suggests that
simvastatin may play a role in calcium metabolism in
postmenopausal women with osteoarthritis. Positive cor-
relation of simvastatin concentration with silicon level
in the plasma suggests that both might prompt the pos-
itive effect of osteoarthritis treatment.
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Abbreviations
BMD Bone mineral density
BMP Bone morphogenetic protein
HMG-CoA 3-Hydroxy-3-methylglutaryl-coenzyme
A reductase
HPLC High-performance liquid chromatography
IL Interleukin
MMP Matrix metalloproteinase
SPE Solid phase extraction
Introduction
Osteoarthritis is the most common joint disease that occurs
mainly in older people, whose physical capability is poorer
[1]. Eighty percent of individuals older than 75 years suffer
from osteoarthritis and its pathogenesis still remain unclear
[2]. It is characterized by destruction of cartilage matrix and
on the joint surface. The process of destruction is followed by
osteophytes production at the joint margins, cystic
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degeneration, and sclerosis on the subchondral bone [3, 4]. At
the synovial area, macrophages and chondrocytes release me-
diators that cause cartilage and bone damages [5]. In early
osteoarthritis, increased production of matrix-degrading en-
zymes such as metalloproteinases has been noticed [4].
Statins, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase inhibitors, including simvastatin, are the one
of the most often prescribed drugs worldwide. The inhibition
of HMG-CoA reductase by statins decreases the synthesis of
mevalonate and isoprenoid units, the intermediates in pathway
of cholesterol biosynthesis, leading to reduction of cholesterol
production. The decrease of isoprenoid units’ synthesis is re-
sponsible also for pleiotropic activity of all statins [6].
Previous studies emphasized the relationship between statins’
activity and bone metabolism. Statins enhance the expression
of the bone morphogenetic proteins (BMPs), in particular of
BMP2, which results in osteoblast differentiation and finally
bone formation. At the same time, statins inhibit osteo-
clastic activity due to decreasing of isoprenoid unit’s
synthesis that is essential for osteoclastic activity [7].
In vitro and in vivo studies have demonstrated an ana-
bolic effect of simvastatin on the bone [8]. Besides,
statins have significant anti-inflammatory and immune-
modulating effects. It has been reported that lipophilic
statins including simvastatin, inhibit expression of
interleukin-1 (IL-1) and matrix metalloproteinases
(MMP-1, MMP-13) in human cartilage [5].
Adult human possesses about 1 kg of calcium in the body,
mostly inside the skeleton. The involvement of calcium into
the mineralization of bones is well understood [9]. The im-
paired calcium intake results in osteoporosis [10]. Intracellular
calcium ions are responsible for signal transduction pathways
including cell proliferation and cell death [11]. On the other
hand, the exact role of silicon is still not clear. There is strong
evidence that dietary silicon is beneficial to bone and connec-
tive tissue health [12].
The interaction between statin and calcium or silicon plas-
ma level in not clear. Previous studies revealed the influence
of rosuvastatin, but not simvastatin, on the elevation of 25-
hydroxyvitamin D level resulting in the increase of calcium
uptake from the digestive tract [13]. However, there is no
information about the role of statins in silicon metabolism.
Menopause decreases intestinal calcium absorption [14]. It
has also been suggested that silicon absorption may decrease
with aging [15], although more recent work did not prove this
to be the case [16]. Imbalance between bone formation and
bone resorption is observed during estrogen deficiency. The
increase of calcium and silicon bioavailability is an important
factor in osteoporosis and osteoarthritis prevention [14].
The aim of our study was to evaluate whether chronic sim-
vastatin treatment (20 or 40 mg/day) could affect calcium and




The study was approved by the Bioethical Committee of the
Medical University in Lublin (No. KE-0254/294/2012) in ac-
cordance with the ethical standards laid down in the 1964
Declaration of Helsinki and its later amendments. All patients
were hospitalized in the Chair of Orthopedics and
Rehabilitation of the Medical University of Lublin, and they
fully agreed to participate in the research constituting the pres-
ent work.
Sixty postmenopausal Caucasian women with knee osteo-
arthritis, evolving more than 6 months, defined according to
American College of Rheumatology (ACR) [17] with an av-
erage age of 61.4 (range 54–68) years were enrolled into the
study. Basic classification criterion was primary slightly ele-
vated total cholesterol level (190–240 mg/dl). The protocol of
the study assumed the enrollment of two equal subgroups of
patients differing with the administration of statins. Because
not of all patients with slightly elevated cholesterol level in the
plasma are treated with lipid-lowering drugs, we chose the
mild hypercholesterolemia as a qualification criterion. Thirty
enrolled patients received simvastatin therapy (20 or 40 mg/
day) for at least 1 year before the study (simvastatin B+^
group). The remaining 30 patients, who did not receive any
statin during the last year, were considered as a control group
(simvastatin B−^ group). All eligible women were in a good
health, based on the physical examination and standard labo-
ratory tests. The potential causes of secondary cholesterol lev-
el elevation (hypothyroidism, chronic steroids intake, liver
and bile ducts disorders, nephrotic syndrome) were not no-
ticed in the study group. Presence of any other diseases that
were able to interfere with bone and joint metabolism espe-
cially immune disorders and obesity were considered as the
exclusion criteria. All patients enrolled into the study did not
use any drugs for osteoarthritis treatment and any other dis-
ease. The characteristic of the study group was given in
Table 1. Dietary calcium and silicon intake was assessed by
interview. The diet rich in these elements was an exclusion
criterion from the study (diet rich in milky and dairy products,
cereals, horsetail, rice, herbaceous plant) [15, 18].
Sample Collection
Venous blood was collected for the evaluation of calcium and
silicon plasma level as well as simvastatin plasma level.
Samples were obtained 3 h after oral simvastatin administra-
tion. All patients were fasted at least 3 h before blood sam-
pling (from simvastatin administration to blood collection).
Typically, simvastatin is administrated in the evening. Due
to logistic reason, the simvastatin administration on the day
of blood collection was moved to 4:00 p.m. The time of blood
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collect ion (3 h after drug administrat ion) was
established on the base of simvastatin mean plasma
concentration-time curve which showed that the drug
plasma level peaked at 3–4 h after administration [19].
After centrifugation, plasma samples were frozen at
−70 °C and stored for further analysis.
Both total silicon and calcium concentrations in the
plasma were determined spectrophotometrically using
the method according to Wielkoszyński [20] and diag-
nostic kit (Cormay, Lublin, Poland), respectively.
Wielkoszyński’s method was based on silicate reaction
with molybdophosphoric acid. Tritrisol–Silicium (Merck)
has been used as a standard, and standard curve was
prepared ranging from 0 to 200 μmol/l, according to
Wielkoszyński’s procedure.
Plasma concentration of simvastatin was determined using
high-performance liquid chromatography (HPLC) with UV-
Vis detector (Gilson, Inc., Middleton, USA) according to the
Nagaraju and Vishnu’s method [21]. The mobile phase
consisting of acetonitrile:phosphate buffer (pH = 4) in the ratio
75:25 v/v was delivered at the flow rate of 1.5 ml/min.
Detection was performed at wavelength 238 nm. The analysis
was carried isocratically on the Kromasil C18 column
(4.6 × 250 mm, 5 μm). Plasma samples were purified using
solid phase extraction (SPE) with Supel-Select HLB SPE
Tubes (Sigma-Aldrich).
Statistics
Student’s t test was applied for analysis of difference between
calcium or silicon plasma level vs. study and control group
(parametric distribution). Pearson correlation coefficient has
been used to establish the relationship between simvastatin,
silicon, and calcium plasma level of postmenopausal women.
All hypotheses were verified at the significance level of
p < 0.05. InStat GraphPad (La Jolla, CA, USA) was applied
for statistical analysis.
Results
Total plasma calcium level was significantly lower in female
patients receiving simvastatin in comparison with non-statins
group (p < 0.05; Fig. 1). Calcium concentration of simvastatin
B+^ group was below the normal range of applied method
(normal range 2.1–2.6 mmol/l). The difference in silicon plas-
ma level between analyzed study groups did not reach statis-
tical significance (p > 0.05; Fig. 1). Plasma silicon concentra-
tion of both study groups remained within the normal range of
the applied method (a reference range is 12.02–30.07 μmol/l).
The mean of free simvastatin level in the plasma was
9.02 ± 1.18 ng/ml. The correlation analysis showed a signifi-
cant positive relationship between silicon and simvastatin lev-
el (r = 0.3, p = 0.03). There was statistically insignificant
(r = −0.2, p = 0.1) negative correlation between calcium and
simvastatin plasma level.
Discussion
The pathogenesis of osteoarthritis in postmenopausal women
still remains unclear. Simvastatin, a lipid-lowering agent, is
the most prescribed drug in the population of postmenopausal
patients. The objective of our study was to evaluate the sim-
vastatin effect on calcium and silicon plasma level in postmen-
opausal, osteoarthritic female patients.
Previous studies have shown that calcium and silicon are
significant elements involved in bone and joint functioning,
especially in older people [9, 12]. Calcium is strongly associ-
ated with bone and joint health. It was reported that women
with low calcium intake more often suffered from osteoporo-
sis and osteoarthritis [1]. Bergillos-Meca et al. [22] showed
that the bioavailability of calcium was significantly higher in
fermented milk containing the probiotic bacteria
Lactobacillus fermentum D3. Our results suggest that simva-
statin can contribute to the decrease of calcium concentration
in the plasma. The negative correlation between simvastatin
vs. calcium plasma levels was observed; however, it did not
reach statistical significance. These findings are surprising in
the light of previous studies that revealed lower incidence of
fracture after statin use. The presence of low calcium in the
blood usually is associated with the increased risk of vertebral
fractures [1], but our results indicated the reduction of calcium
in simvastatin-treated group. Tikiz et al. [23] reported that
simvastatin treatment affects bone metabolism positively in a
short time period. Clockaerts et al. [24] showed that statin use
is strongly associated with more than 50 % reduction in pro-
gression of osteoarthritis of the knee. Observed decrease of
calcium plasma level in simvastatin-treated group theoretical-
ly can be due to the intense use of calcium for bone recovery.
Table 1 The characteristic of
study group Simvastatin + Simvastatin − t test
Number 30 30 NA
Age (years) 60.7 ± 3.8 62.2 ± 3.9 p > 0.05
Mean total cholesterol level (mg/dl) 214.7 ± 12.7 211.8 ± 13.8 p > 0.05
Simvastatin 20/40 mg (n) 24/6 NA NA
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Unfortunately, other study did find neither the stimulation of
bone formation by simvastatin nor an elevation of osteoblast
activity under in vivo conditions [25].
The dietary consumption of trace elements including
silicon has been previously correlated with bone mass
[12, 25]. Decreased incidences of bone fracture have
been found in Asians and Indians, whose foods are
relatively rich in various nutrients including silicon
[26]. On the basis of the study performed on ovariecto-
mized rats, Kim et al. [27] put forward the hypothesis
that silicon supplementation can prevent osteoporosis in
postmenopausal women whose calcium intake is insuf-
ficient. It has been found that oral silicon administration
results in an increase in the bone density and improves
bone formation [28]. Jugdaohsingh et al. [12] suggested
that higher dietary silicon intake in men and young
women might be beneficial in their skeletal health.
They suggested as well that hormonal changes after
menopause attenuate any positive effect on the bone.
Silicon intake is strongly associated with bone mineral
density (BMD) in premenopausal women, whereas no
correlation has been found in postmenopausal women
[28]. To the best of our knowledge, this is the first
study evaluating the effect of simvastatin on silicon
plasma level. Although no significant difference in sili-
con plasma level between simvastatin-treated and non-
treated group was found, the positive correlation be-
tween simvastatin and silicon plasma levels can suggest
that the statin is one of the potential factor affecting
silicon concentration in the plasma. Nevertheless, the
correlation between silicon plasma level and simvastatin
is weak, probably due to the fact that the simvastatin
contains silicon dioxide as an inactive ingredient. Due
to unclear metabolism of silicon, the direct mechanism
of statins on silicon plasma level is still the subject of
speculation. Further in vivo and in vitro studies should
be focused on explanation of molecular mechanism of
simvastatin and other statins influence on calcium and
silicon plasma levels.
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